Abstract
We generated and compared the mutation profiles through targeted sequencing of the primary tumors and matched bone marrow/peripheral blood samples in 25 patients with angioimmunoblastic T-cell lymphoma (AITL) and 2 with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Our results provided strong evidence that AITL/PTCL-NOS, clonal hematopoiesis (CH) as well as other concomitant myeloid and even B-cell hematologic neoplasms (CHN), frequently arose from common mutated hematopoietic stem cell clones. Aberrant AID/APOBEC activity-associated substitutions and tobacco smoking-associated substitutions were enriched in the early CH-associated mutations and late non-CH associated mutations during AITL/PTCL-NOS development, respectively. Moreover, survival analysis showed that the presence of CH harboring ≥ 2 pathogenic TET2 variants with ≥ 15% of allele burden conferred higher risk for CHN (P = 0.0034, hazard ratio = 10.81). These findings provide insights into the cell origin and etiology of AITL, and provide a novel stratification biomarker for CHN risk in AITL/PTCL-NOS patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by a grant (R01 CA194547) from the National Cancer Institute to Dr. Wayne Tam.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Institutional Review Board of Weill Cornell Medicine, New York, USA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are provided or available upon request.
Abbreviations
- AITL
- angioimmunoblastic T cell lymphoma
- PTCL-NOS
- peripheral T cell lymphoma, not otherwise specified
- CH
- clonal hematopoiesis
- CHN
- concomitant hematologic neoplasm
- DLBCL
- diffuse large B cell lymphoma
- MPN
- myeloproliferative neoplasm
- TET2
- Ten-Eleven Translocation-2
- VAF
- variant allele frequency
- Ti
- nucleotide transition substitution
- Tv
- nucleotide transverse substitution
- PPV
- positive predictive value
- NPV
- negative predictive value
